IL117237A - Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form - Google Patents

Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form

Info

Publication number
IL117237A
IL117237A IL11723796A IL11723796A IL117237A IL 117237 A IL117237 A IL 117237A IL 11723796 A IL11723796 A IL 11723796A IL 11723796 A IL11723796 A IL 11723796A IL 117237 A IL117237 A IL 117237A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
dosage form
unit dosage
solid unit
piperidinoalkanol compounds
Prior art date
Application number
IL11723796A
Other languages
English (en)
Other versions
IL117237A0 (en
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27015322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL117237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Priority to IL13477096A priority Critical patent/IL134770A/en
Priority to IL13476996A priority patent/IL134769A/en
Priority to IL13477296A priority patent/IL134772A/en
Priority to IL13477196A priority patent/IL134771A/en
Publication of IL117237A0 publication Critical patent/IL117237A0/xx
Priority to IL13477200A priority patent/IL134772A0/xx
Priority to IL13477000A priority patent/IL134770A0/xx
Priority to IL13476900A priority patent/IL134769A0/xx
Priority to IL13477100A priority patent/IL134771A0/xx
Publication of IL117237A publication Critical patent/IL117237A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL11723796A 1995-02-28 1996-02-23 Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form IL117237A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IL13477096A IL134770A (en) 1995-02-28 1996-02-23 Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
IL13476996A IL134769A (en) 1995-02-28 1996-02-23 Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
IL13477296A IL134772A (en) 1995-02-28 1996-02-23 Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
IL13477196A IL134771A (en) 1995-02-28 1996-02-23 Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
IL13477200A IL134772A0 (en) 1995-02-28 2000-02-28 Pharmaceutical compositions for piperidinoalkanol compounds in solid unit dosage form
IL13477000A IL134770A0 (en) 1995-02-28 2000-02-28 Pharmaceutical compositions for piperidinolalkanol compounds in solid unit dosage form
IL13476900A IL134769A0 (en) 1995-02-28 2000-02-28 Pharmaceutical compositions for piperidinoalkanol compounds in solid unit dosage form
IL13477100A IL134771A0 (en) 1995-02-28 2000-02-28 Pharmaceutical compositions for piperidinoalkanol compounds in solid unit dosage form

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39595295A 1995-02-28 1995-02-28
US55228795A 1995-12-12 1995-12-12

Publications (2)

Publication Number Publication Date
IL117237A0 IL117237A0 (en) 1996-06-18
IL117237A true IL117237A (en) 2001-01-11

Family

ID=27015322

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11723796A IL117237A (en) 1995-02-28 1996-02-23 Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form

Country Status (22)

Country Link
US (9) US5738872A (no)
EP (1) EP0812195B1 (no)
JP (3) JP4105762B2 (no)
KR (1) KR100405116B1 (no)
CN (1) CN1090935C (no)
AR (1) AR003929A1 (no)
AT (1) ATE226819T1 (no)
AU (1) AU701042B2 (no)
CA (1) CA2213700C (no)
CL (1) CL2004000317A1 (no)
DE (1) DE69624559T2 (no)
DK (1) DK0812195T3 (no)
ES (1) ES2181868T3 (no)
FI (1) FI973518A0 (no)
HU (1) HUP9802086A3 (no)
IL (1) IL117237A (no)
MX (1) MX9706449A (no)
NO (2) NO325760B1 (no)
NZ (1) NZ302926A (no)
PT (1) PT812195E (no)
TW (1) TW460284B (no)
WO (1) WO1996026726A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135571B2 (en) 1994-05-18 2006-11-14 Aventis Pharmaceuticals, Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP0812195B1 (en) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
US7091183B1 (en) * 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
IL133420A (en) * 1997-08-26 2004-07-25 Aventis Pharma Inc Tablet-shaped pharmaceutical preparation containing a combination of piperidinoalkanol and antihistamines and reduces symptomatic congestion
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
NZ504994A (en) * 1997-12-22 2002-10-25 Schering Corp Orally administrable rapidly dissolving solid ribavirin dosage forms
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
DE1292303T1 (de) * 2000-02-17 2003-09-18 Teva Pharma Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US8155096B1 (en) 2000-12-01 2012-04-10 Ipr Licensing Inc. Antenna control system and method
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
US6569454B2 (en) * 2001-02-27 2003-05-27 Minh Van Nguyen Simple tablet compression using gelatin
WO2002080857A2 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
WO2003011295A1 (en) * 2001-07-31 2003-02-13 Texcontor Etablissement Fexofenadine polymorph
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003243191B2 (en) * 2002-05-02 2007-09-20 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20040044038A1 (en) * 2002-06-10 2004-03-04 Barnaba Krochmal Polymorphic form XVI of fexofenadine hydrochloride
WO2004062647A1 (en) * 2003-01-03 2004-07-29 Minh Nguyen Simple tablet compression using gelatin
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
MXPA06012281A (es) * 2004-04-26 2007-07-18 Teva Pharma Formas cristalinas de clorhidrato de fexofenadina y procesos para su preparacion.
US20060148851A1 (en) * 2004-09-28 2006-07-06 Shlomit Wizel Fexofenadine crystal form and processes for its preparation thereof
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
PT1729735E (pt) * 2004-11-10 2007-08-06 Teva Pharma Processo de produção de formas de dosagens sólidas comprimidas adequado para utilização com fármacos de baixa solubilidade em água e formas de dosagens sólidas comprimidas assim obtidas
AU2006250340C1 (en) 2005-05-26 2014-06-12 Sumitomo Pharma Co., Ltd. Pharmaceutical composition
KR100735904B1 (ko) 2005-08-02 2007-07-04 주식회사 드림파마 한방 건조엑스 함유 정제 조성물 및 그를 이용한 한방건조엑스 함유 정제의 제조방법
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
WO2007052310A2 (en) * 2005-11-03 2007-05-10 Morepen Laboratories Limited Polymorphs of fexofenadine hydrochloride and process for their preparation
WO2007114921A2 (en) 2006-04-05 2007-10-11 Schering Corporation Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5] decan-2-one and treatment methods using the same
EP2144599B1 (en) * 2007-03-02 2010-08-04 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
WO2010141850A1 (en) * 2009-06-05 2010-12-09 Entrigue Surgical, Inc. Systems and devices for providing therapy of an anatomical structure
SG10201407538WA (en) 2009-08-14 2015-01-29 Opko Health Inc Intravenous formulations of neurokinin-1 antagonists
FR2959130A1 (fr) 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
FR2999937B1 (fr) 2012-12-21 2015-01-09 Sanofi Sa Unite solide a haute teneur en fexofenadine et son procede de preparation
AR094761A1 (es) 2013-02-14 2015-08-26 Sanofi Sa Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma
US10130620B2 (en) 2013-07-01 2018-11-20 Aventisub Llc Liquid pharmaceutical composition for oral administration comprising fexofenadine
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
EP3002005A1 (en) 2014-09-30 2016-04-06 Molkerei Meggle Wasserburg GmbH & Co. Kg Direct compression excipient based on lactose, cellulose and starch
KR101825041B1 (ko) * 2016-04-07 2018-02-02 주식회사 바이오솔루션 물질 p를 포함하는 상처치유용 약학 조성물

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US3806526A (en) * 1972-01-28 1974-04-23 Richardson Merrell Inc 1-aroylalkyl-4-diphenylmethyl piperidines
DE2348334C2 (de) * 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
US3941795A (en) * 1974-02-08 1976-03-02 Richardson-Merrell Inc. α-ARYL-4-SUBSTITUTED PIPERIDINOALKANOL DERIVATIVES
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4254130A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
US4493528A (en) * 1980-04-11 1985-01-15 Board Of Trustees Of The Leland Stanford Junior University Fiber optic directional coupler
EP0111114A3 (de) * 1982-11-06 1985-10-09 Telefonbau und Normalzeit GmbH Schaltungsanordnung für eine Fernsprechvermittlungsanlage, insbesondere Fernsprechnebenstellenanlage mit zusätzlichem Datenverkehr
GB8613811D0 (en) * 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
DK164642C (da) * 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US4963540A (en) * 1986-04-16 1990-10-16 Maxson Wayne S Method for treatment of premenstrual syndrome
SE8603812D0 (sv) * 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
DE3720493A1 (de) * 1987-06-20 1989-01-26 Nattermann A & Cie Arzneizubereitungen mit mikronisierten ebselen-kristallen
CN1053570C (zh) * 1987-10-07 2000-06-21 默尔多药物公司 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
SE8804173A0 (sv) * 1988-11-18 1990-05-19 Lim Johan Ab Insektsfångare
ZA90341B (en) * 1989-01-23 1990-10-31 Merrell Dow Pharma Liquid pharmaceutical composition for piperidinoalkanol derivatives
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5516803A (en) * 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
CA2125666C (en) * 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
WO1993021156A1 (en) 1992-04-10 1993-10-28 Merrell Dow Pharmaceuticals Inc. 4-diphenylmethyl piperidine derivatives and process for their preparation
HU223774B1 (hu) 1992-05-11 2005-01-28 Merrell Dow Pharmaceuticals Inc. Terfenadinszármazékok alkalmazása antihisztamin hatású gyógyszerkészítmények előállítására
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
ATE363283T1 (de) * 1992-08-03 2007-06-15 Sepracor Inc Terfenadin-carboxylat und die behandlung von hautreizung
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
DE69415319T2 (de) * 1993-06-24 1999-06-10 Albany Molecular Research, Inc., Albany, N.Y. Verfahren zur herstellung von piperidinderivaten
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US5895664A (en) * 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US20030045722A1 (en) 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CA2449419C (en) * 1994-05-18 2011-09-06 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
EP0812195B1 (en) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
US6451815B1 (en) 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
AU725965C (en) * 1997-08-14 2004-04-22 Aventisub Llc Method of enhancing bioavailability of fexofenadine and its derivatives
IL133420A (en) 1997-08-26 2004-07-25 Aventis Pharma Inc Tablet-shaped pharmaceutical preparation containing a combination of piperidinoalkanol and antihistamines and reduces symptomatic congestion

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135571B2 (en) 1994-05-18 2006-11-14 Aventis Pharmaceuticals, Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US7666881B2 (en) 1994-05-18 2010-02-23 Aventis Holdings, Inc. Methods of treating allergic reactions using hydrated forms of antihistaminic piperidine derivatives

Also Published As

Publication number Publication date
EP0812195B1 (en) 2002-10-30
US8129408B2 (en) 2012-03-06
AU701042B2 (en) 1999-01-21
JP4105762B2 (ja) 2008-06-25
US20070249671A1 (en) 2007-10-25
KR100405116B1 (ko) 2004-02-05
EP0812195A1 (en) 1997-12-17
CA2213700C (en) 2002-04-02
PT812195E (pt) 2003-03-31
US5738872A (en) 1998-04-14
WO1996026726A1 (en) 1996-09-06
KR19980702575A (ko) 1998-07-15
NO973938L (no) 1997-10-28
IL117237A0 (en) 1996-06-18
FI973518A (fi) 1997-08-27
ATE226819T1 (de) 2002-11-15
CN1090935C (zh) 2002-09-18
HUP9802086A2 (hu) 1999-01-28
US5932247A (en) 1999-08-03
AU4909896A (en) 1996-09-18
JP2008266347A (ja) 2008-11-06
NO20065390L (no) 1997-10-28
NZ302926A (en) 1998-10-28
CA2213700A1 (en) 1996-09-06
FI973518A0 (fi) 1997-08-27
US20010022973A1 (en) 2001-09-20
US5855912A (en) 1999-01-05
HUP9802086A3 (en) 2001-02-28
DK0812195T3 (da) 2003-03-03
US20100021547A1 (en) 2010-01-28
JP4177787B2 (ja) 2008-11-05
US20020106405A1 (en) 2002-08-08
DE69624559D1 (de) 2002-12-05
ES2181868T3 (es) 2003-03-01
US20030203020A1 (en) 2003-10-30
US6113942A (en) 2000-09-05
NO973938D0 (no) 1997-08-27
NO325760B1 (no) 2008-07-14
CL2004000317A1 (es) 2005-01-21
TW460284B (en) 2001-10-21
AR003929A1 (es) 1998-09-30
MX9706449A (es) 1997-11-29
CN1176599A (zh) 1998-03-18
JPH11501028A (ja) 1999-01-26
DE69624559T2 (de) 2003-07-10
JP2004292459A (ja) 2004-10-21

Similar Documents

Publication Publication Date Title
IL117237A (en) Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
IL122618A0 (en) Substituted imidazolylacetonitrile compounds their preparation and pharmaceutical compositions containing them
IL116957A0 (en) Substituted heterocyclic compounds their preparation and pharmaceutical compositions containing them
IL119078A (en) Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them
IL117728A0 (en) Pharmaceutical compositions for transdermal administration
IL117041A0 (en) Oral pharmaceutical dosage form
GB9410987D0 (en) High dosage pharmaceutical compositions
IL116455A0 (en) Imidazole compounds and pharmaceutical compositions containing them
IL117860A0 (en) Substituted 1-phenyl-3-pyrazolecarboxamides their preparation and pharmaceutical compositions containing them
HUP9801995A3 (en) Substituted pyrimidine-thioalkyl and alkylether compounds and their use for producing pharmaceutical compositions
IL122717A0 (en) Compounds and pharmaceutical compositions containing them
IL122293A0 (en) Substituted 4-phenylaminothiazoles their preparation and pharmaceutical compositions containing them
IL119559A0 (en) Purin -6- one derivatives their preparation and pharmaceutical compositions containing them
IL117554A0 (en) Imidazoquinazolines their preparation and pharmaceutical compositions containing them
IL122705A (en) 2-(4-Susbstituted)-benzylamino-2-methyl-propanamide derivatives their preparation and pharmaceutical compositions containing them
HUT74746A (en) Pharmaceutical compositions containing p antagonist
IL117817A0 (en) N-subsituted azaheterocyclic compounds their preparation and pharmaceutical compositions containing them
IL116771A (en) 9-Substituted 2-(2-n-alkoxyphenyl) purin-6-one compounds their preparation and pharmaceutical compositions containing them
EG24294A (en) Pharmaceutical compositions
GB9506382D0 (en) Pharmaceutical compositions
GB9513972D0 (en) Pharmaceutical compositions
IL119371A0 (en) Sulfonylaminopyrimidines their preparation and pharmaceutical compositions containing them
IL118672A0 (en) Benzisothiazolyl-substituted aminomethylchromans their preparation and pharmaceutical compositions containing them
ZA964517B (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
IL117395A0 (en) Bicyclic compounds preparation thereof and use in pharmaceutical compositions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired